• Our Brands
    • Alma
    • LMNT
    • Copulla
    • Injectables
  • About us
    • Our Story
    • Management Team
  • News & Press Release
    • News & Press Release
    • Social Media
  • Investor Relations
  • Contact us
  • English
    • 简体中文
    • 繁體中文
Home  >   Investors   >  Corporate Governance

Investors

  • Overview
    • Board of Directors
    • Corporate Information
    • Corporate Videos
  • HKEx Filings
  • Financial Reports
  • Analyst Coverage
  • Stock Information
  • Corporate Governance
  • IR Events & Presentations
  • Dissemination of Corporate Communications by Electronic Means
  • IR Contact

Corporate Governance

Audit Committee

The Company has established the audit committee in compliance with Rule 3.21 of the Listing Rules, the Corporate Governance Code as set out in Appendix 14 to the Listing Rules and will be confirmed following ratification of the external directors in accordance with the Israeli Companies Law.

 

The primary duties of the audit committee are to oversee the financial reporting system and internal control procedures of the Company, review the financial information of the Company and consider issues relating to the external auditors and their appointment. See “Appendix IV—Summary of the Israeli Companies Law, Shareholder Protection Matters and Voting Arrangements” in this prospectus for details of the requirements of an audit committee under the Israeli Companies Law.

 

The audit committee consists of three Directors. The members of the audit committee are:
Mr. Heung Sang Addy FONG (Chairman)
Ms. Jenny CHEN
Mr. Chi Fung Leo CHAN

 

 

 

Remuneration Committee

The Company has established a remuneration committee of the Board in compliance with Rule 3.25 of the Listing Rules, the Corporate Governance Code as
set out in Appendix 14 to the Listing Rules and will be confirmed following ratification of the external directors in accordance with the Israeli Companies Law.

 

The primary duties of the remuneration committee are to make recommendations to the Board on the Company’s policy and structure for all remuneration of directors
and senior management and on the establishment of a formal and transparent procedure for developing policy on such remuneration. See “Appendix IV—Summary of the Israeli Companies Law, Shareholder Protection Matters and Voting Arrangements” in this prospectus for details of the requirements of a remuneration or compensation committee under the Israeli Companies Law.

The remuneration committee consists of three Directors. The members of the remuneration committee are:
Mr. Yi LIU (Chairman)
Mr. Heung Sang Addy FONG
Mr. Chi Fung Leo CHAN

 

 

 

 

Nomination Committee

The Company has established a nomination committee of the Board as recommended by the Corporate Governance Code as set out in Appendix 14 to the Listing Rules.

 

The primary duties of the nomination committee are to review the structure, size and composition of the Board, assess the independence of the independent
non-executive directors and make recommendations to the Board on the appointment and re-appointment of directors and succession planning for directors.

 

The nomination committee consists of three Directors. The members of the nomination committee are:
Mr. Yi LIU (Chairman)
Mr. Chi Fung Leo CHAN
Mr. Heung Sang Addy FONG

Corporate Governance

  • Corporate Governance Manual
  • Articles of Association
  • List of Directors and Roles
  • Audit Committee Terms
  • Terms of Remuneration Committee
  • Terms of Nomination Committee
  • Procedures for Shareholders
futu page QR

Sisram Medical Ltd

OFEK 15 Building, 18 HaHarash Street, Industrial Park- Caesarea, 3079895, Israel

+972-4-6275357

For more information, please contact us

[email protected]

Follow us:

  • linkedin
  • futu
sisram logo

Main

  • Our Story
  • Management Team

Our Brands

  • Alma
  • LMNT
  • Copulla
  • Injectables

Investors

  • Overview
  • News & Press Release
  • HKEx Filings
  • Financial Reports
  • Corporate Governance
  • Dissemination of Corporate Communications by Electronic Means
  • IR Contact

10105

Sisram Medical 2024 Annual Results Presentation
 Sisram Medical 2024 Annual Results Presentation
Mar 20, 2025
  • Terms of Use
  • Privacy Policy

© 2025 Sisram Medical Ltd

  • 简体中文 (Chinese (Simplified))
  • 繁體中文 (Chinese (Traditional))
  • English